VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

被引:116
作者
Le Gouill, S
Podar, K
Amiot, M
Hideshima, T
Chauhan, D
Ishitsuka, K
Kumar, S
Raje, N
Richardson, PG
Harousseau, JL
Anderson, KC [1 ]
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02215 USA
[2] CHU Nantes, Hotel Dieu, Serv Hematol Clin, F-44035 Nantes 01, France
[3] CHU Nantes, Hotel Dieu, Inst Biol, UO601,INSERM, F-44035 Nantes 01, France
关键词
D O I
10.1182/blood-2004-05-1760
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Interleukin-6 (IL-6) triggers multiple myeloma (MM) cell proliferation and protects against apoptosis by up-regulating myeloid cell leukemia 1 (Mcl-1). Vascular endothelial growth factor (VEGF) induces modest proliferation of MM cells and induces IL-6 secretion in a paracrine loop involving MM cells and bone marrow stromal cells. Using murine embryonic fibroblast cell lines as a model (Mcl-1(wt/wt) and Mcl-1(Delta/null) MEFs), we here demonstrate that deletion of Mcl-1 reduces fetal bovine serum (FBS)-, VEGF-, and IL-6-induced proliferation. We also show that VEGF up-regulates Mcl-1 expression in a time and dose-dependent manner in 3 human MM cell lines and MM patient cells. Importantly, we demonstrate that the pan-VEGF inhibitor, GW654652, inhibits VEGF-induced up-regulation of Mcl-1 and, as with Mcl-1 siRNA, is associated with decreased proliferation and induction of apoptosis. Finally, we show that VEGF protects MM patient cells against FBS starvation-induced apoptosis. Our studies therefore demonstrate that VEGF-induced MM cell proliferation and survival are mediated via Mcl-1, providing the preclinical framework for novel therapeutics targeting Mcl-1 and/or VEGF to improve patient outcome in MM. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:2886 / 2892
页数:7
相关论文
共 46 条
[1]   Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting [J].
Ambrosini, G ;
Adida, C ;
Sirugo, G ;
Altieri, DC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (18) :11177-11182
[2]  
Bellamy WT, 1999, CANCER RES, V59, P728
[3]  
Chauhan D, 2003, CANCER RES, V63, P6174
[4]   2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells [J].
Chauhan, D ;
Catley, L ;
Hideshima, T ;
Li, GL ;
Leblanc, R ;
Gupta, D ;
Sattler, M ;
Richardson, P ;
Schlossman, RL ;
Podar, K ;
Weller, E ;
Munshi, N ;
Anderson, KC .
BLOOD, 2002, 100 (06) :2187-2194
[5]   MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis [J].
Craig, RW .
LEUKEMIA, 2002, 16 (04) :444-454
[6]   Cell death: Critical control points [J].
Danial, NN ;
Korsmeyer, SJ .
CELL, 2004, 116 (02) :205-219
[7]  
Dankbar Berno, 2000, Blood, V95, P2630
[8]   Antisense strategy shows that Mcl-1 rather than Bcl-2 or BCI-xL is an essential survival protein of human myeloma cells [J].
Derenne, S ;
Monia, B ;
Dean, NM ;
Taylor, JK ;
Rapp, MJ ;
Harousseau, JL ;
Bataille, R ;
Amiot, M .
BLOOD, 2002, 100 (01) :194-199
[9]   VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition [J].
Dias, S ;
Shmelkov, SV ;
Lam, G ;
Rafii, S .
BLOOD, 2002, 99 (07) :2532-2540
[10]   Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy [J].
Dias, S ;
Choy, M ;
Alitalo, K ;
Rafii, S .
BLOOD, 2002, 99 (06) :2179-2184